Top

Published in:

01-08-2012 | Focussed Research Review

CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer

Authors: Markus Chmielewski, Hinrich Abken

Published in: Cancer Immunology, Immunotherapy | Issue 8/2012

Abstract

Adoptive T cell therapy recently achieved impressive efficacy in early-phase clinical trials; this significantly raises the profile of immunotherapy in the fight against cancer. A broad variety of tumour cells can specifically be targeted by patients’ T cells, which are redirected in an antibody-defined, major histocompatibility complex–unrestricted fashion by endowing them with a chimeric antigen receptor (CAR). Despite promising results for some haematologic malignancies, the stroma of large, established tumours, the broad plethora of infiltrating repressor cells, and cancer cell variants that had lost the target antigen limit their therapeutic efficacy in the long term. This article reviews a newly described strategy for overcoming some of these shortcomings by engineering CAR T cells with inducible or constitutive release of IL-12. Once redirected, these T cells are activated, and released IL-12 accumulates in the tumour lesion where it promotes tumour destruction by at least two mechanisms: (1) induction of an innate immune cell response towards those cancer cells which are invisible to redirected T cells and (2) triggering programmatic changes in immune-suppressive cells. Given the enormous complexity of both tumour progression and immune attack, the upcoming strategies using CAR-redirected T cells for local delivery of immune-modulating payloads exhibited remarkable efficacy in pre-clinical models, suggesting their evaluation in clinical trials.

Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE (2010) Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 10:77–90PubMedCrossRef

Hombach AA, Abken H (2011) Costimulation by chimeric antigen receptors revisited the T cell antitumour response benefits from combined CD28-OX40 signalling. Int J Cancer 129:2935–2944PubMedCrossRef

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumour effects and can establish memory in patients with advanced Leukemia. Sci Transl Med 3:95ra73PubMedCrossRef

Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumour and immune cells in orchestrating the immunosuppressive network at the tumour microenvironment. Cancer Immunol Immunother 56:1687–1700PubMedCrossRef

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727PubMedCrossRef

Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA et al (2010) Tumour-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70:6725–6734PubMedCrossRef

Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumour cells that have shut down tumour antigen expression. Cancer Res 71:5697–5706PubMedCrossRef

Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumours. J Clin Invest 121:4746–4757PubMedCrossRef

Trinchieri G, Pflanz S, Kastelein RA (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19:641–644PubMedCrossRef

10.

Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547–549PubMedCrossRef

11.

Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumour immune response. J Exp Med 188:2357–2368PubMedCrossRef

12.

Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ (2003) Intratumoural delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 63:6378–6386PubMed

13.

Wesa A, Kalinski P, Kirkwood JM, Tatsumi T, Storkus WJ (2007) Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. J Immunother 30:75–82PubMedCrossRef

14.

Yoo JK, Cho JH, Lee SW, Sung YC (2002) IL-12 provides proliferation and survival signals to murine CD4+ T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 169:3637–3643PubMed

15.

Curtsinger JM, Lins DC, Mescher MF (2003) Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197:1141–1151PubMedCrossRef

16.

Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20:561–567PubMedCrossRef

17.

Coughlin CM, Salhany KE, Wysocka M, Aruga E, Kurzawa H, Chang AE, Hunter CA, Fox JC, Trinchieri G, Lee WM (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumour regression which involves inhibition of angiogenesis. J Clin Invest 101:1441–1452PubMedCrossRef

18.

Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT (1996) B7.1 costimulation markedly enhances IL 12-mediated antitumour immunity in vivo. Eur J Immunol 26:1335–1341PubMedCrossRef

19.

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146PubMedCrossRef

20.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F et al (2006) Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science 313:1960–1964PubMedCrossRef

21.

Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A (2000) Peripheral burst of tumour-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 60:3559–3568PubMed

22.

van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, Adema GJ, De Mulder PH (2005) Intratumoural recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumour. Clin Cancer Res 11:1899–1909PubMedCrossRef

23.

Car BD, Eng VM, Lipman JM, Anderson TD (1999) The toxicology of interleukin-12: a review. Toxicol Pathol 27:58–63PubMedCrossRef

24.

Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumours. Science 278:1623–1626PubMedCrossRef

25.

Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA, Nam SJ et al (2001) Interleukin 12 gene therapy of cancer by peritumoural injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12:671–684PubMedCrossRef

26.

Sun Y, Jurgovsky K, Moller P (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481–490PubMedCrossRef

27.

Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K (2005) Intratumoural injection of DNA encoding human interleukin-12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16:35–48PubMedCrossRef

28.

Curti A, Parenza M, Colombo MP (2003) Autologous and MHC class I-negative allogeneic tumour cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 101:568–575PubMedCrossRef

29.

Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B (2010) IL-12 initiates tumour rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 11:1030–1038PubMedCrossRef

30.

Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda MJ, Colombo MP, Forni G (1997) Antitumour efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049–1058PubMedCrossRef

31.

Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM (2004) A strategy for treatment of Epstein–Barr virus-positive Hodgkin’s disease by targeting interleukin 12 to the tumour environment using tumour antigen-specific T cells. Cancer Gene Ther 11:81–91PubMedCrossRef

32.

Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, Rosenberg SA, Morgan RA (2011) Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumour environment. Mol Ther 19:751–759PubMedCrossRef

33.

Fan H, Walters CS, Dunston GM, Tackey R (2002) IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine 19:126–137PubMedCrossRef

34.

Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP (1993) Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 151:2444–2452PubMed

35.

Dowell AC, Oldham KA, Bhatt RI, Lee SP, Searle PF (2011) Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12. Cancer Immunol Immunother. doi:10.1007/s00262-011-1122-3

36.

Díaz-Montero CM, Naga O, Zidan AA, Salem ML, Pallin M, Parmigiani A, Walker G, Wieder E, Komanduri K, Cole DJ, Montero AJ et al (2011) Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumour clearance and anti-tumour memory. Am J Cancer Res 1:882–896PubMed

37.

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D (2011) Tumour-infiltrating myeloid cells induce tumour cell resistance to cytotoxic T cells in mice. J Clin Invest 121:4015–4029PubMedCrossRef

38.

Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumours. Nat Med 10:294–298PubMedCrossRef

39.

Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD et al (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumour-specific CD8+ T cells. J Exp Med 202:907–912PubMedCrossRef

40.

Hunter CA (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5:521–531PubMedCrossRef

41.

Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F et al (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13:715–725PubMedCrossRef

42.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465PubMedCrossRef

43.

Ju DW, Yang Y, Tao Q, Song WG, He L, Chen G, Gu S, Ting CC, Cao X (2000) Interleukin-18 gene transfer increases antitumour effects of suicide gene therapy through efficient induction of antitumour immunity. Gene Ther 7:1672–1679PubMedCrossRef

44.

Munder M, Mallo M, Eichmann K, Modolell M (1998) Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 187:2103–2108PubMedCrossRef

45.

Durrant DM, Metzger DW (2010) IL-12 can alleviate Th17-mediated allergic lung inflammation through induction of pulmonary IL-10 expression. Mucosal Immunol 3:301–311PubMedCrossRef

46.

Egilmez NK, Harden JL, Virtuoso LP, Schwendener RA, Kilinc MO (2011) Nitric oxide short-circuits interleukin-12-mediated tumour regression. Cancer Immunol Immunother 60:839–845PubMedCrossRef

47.

Rosenberg SA (2011) Cell therapy for metastatic melanoma using CD8 enriched tumour infiltrating lymphocytes. http://www.ClinicalTrials.gov. NCT01236573

Title: CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
Authors: Markus Chmielewski
Hinrich Abken
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 8/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-012-1202-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2012

Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

The expression, function, and clinical relevance of B7 family members in cancer

Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding

Harnessing human plasmacytoid dendritic cells as professional APCs

FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer